STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION 
For procedures finalised after 1 September 2004 please refer to module 8B.  
• 
• 
• 
• 
• 
• 
The Marketing Authorisation Holder submitted to the EMEA on 28 August 1997 an application 
for three type I variations falling within the scope of item No. 11 and item No. 16 of Annex I to 
Commission Regulation (EC) No 542/95. The Marketing Authorisation Holder applied for: 
1. 
2. 
Change in the manufacturers involved in the manufacture of the active substance, i.e. the 
addition of another manufacturer, Omnichem N.V. (Belgium). 
Change in the manufacturers involved in the manufacture of the active substance, i.e. the 
addition of another manufacturer, Squibb Manufacturing Inc. (Puerto Rico).  
3. 
Increase in the granulation batch size for the finished product intended for marketing. 
On  4  September  1997,  the  EMEA  approved  the  variations.  These  variations  did  not  require 
amendments to the Commission Decision.  
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  10  September  1997  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No.  11  of  Annex  I  to 
Commission Regulation (EC) No 542/95. The Marketing Authorisation Holder applied for: 
Change  in  the  manufacturers  involved  in  the  manufacture  of  the  active  substance,  i.e.  the 
addition of another manufacturer, Orgamol SA  (Switzerland).  
On  17  October  1997,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision.  
The Marketing Authorisation Holder submitted to the EMEA on 12 January 1998 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  12  of  Annex  I  to  Commission 
Regulation (EC) No 542/95. The Marketing Authorisation Holder applied for: 
A minor change of the manufacturing process of the active substance  
On  20  February  1998,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision.  
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  08  June  1998  an  application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  11  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
An alternative manufacturer for the active substance.  
On  07  August  1998,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision.  
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  22  September  1998  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  15  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
A  change  in  the  manufacture  of  the  medicinal  product,  specifically  an  alternative  powder 
transferring process. 
On  23  October  1998,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision.  
On  25  September  1998  The  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended.  The scope of the variation related to the update in the SPC and PL 
according  to  the  irbesartan-specific  information  provided  in  the  CoAprovel  positive  opinion. 
The wording of the legal status has also been updated in Annex II of the Commission decision.  
On 17 December 1998 the CPMP approved the variation. The variation required amendments in 
the  relevant  sections  of  the  Commission  Decision  and  the  EPAR.  The  European  Commission 
amended the Decision on 13 April 1999. In addition, the scientific discussion on efficacy of the 
EPAR was updated with more detailed information. 
1/4 
   EMEA 2004 
 
 
 
 
 
 
 
 
• 
• 
• 
• 
• 
• 
• 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  30  September  1998  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  3  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
A change in the address of the marketing authorisation holder. 
On 05 November 1998, the EMEA approved the variation. The variation required amendments 
in the relevant sections of the Commission decision. The respective Commission Decision was 
issued on 23 February 1999. 
The  Marketing  Authorisation  Holder  submitted  to  the  EMEA  on  18  December  1998  an 
application  for  one  type  I  variation  falling  within  the  scope  of  item  No  11b  of  Annex  I  to 
Commission  Regulation  (EC)  No  542/95,  as  amended.  The  Marketing  Authorisation  Holder 
applied for: 
An alternative manufacturer for one step of the manufacturing process of the active substance. 
On  20  January  1999,  the  EMEA  approved  the  variation.  This  variation  did  not  require 
amendments to the Commission Decision.  
The Marketing Authorisation Holder submitted to the EMEA on 24 March 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  1  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
An authorisation of a second European site responsible for batch release for the EU. 
On  28  April  1999,  the  EMEA  issued  the  corresponding  notification.  This  variation  required 
amendments to the Commission Decision. The respective Commission Decision was issued on 
16 June 1999.  
The Marketing Authorisation Holder submitted to the EMEA 26 April 1999 an application for 
one  type  I  variation  falling  within  the  scope  of  item  No  12a  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
Changes in the specification of starting material used in the manufacture of the active substance. 
On 1 June 1999, the EMEA issued the corresponding notification. This variation did not require 
amendments to the Commission Decision.  
The Marketing Authorisation Holder submitted to the EMEA 5 August 1999 an application for 
one  type  I  variation  falling  within  the  scope  of  item  No  11b  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
An  alternative  supplier  of  an  intermediate  compound  used  in  the  manufacture  of  the  active 
substance. 
On 8 September 1999, the EMEA issued the corresponding notification. This variation did not 
require amendments to the Commission Decision.  
On  8  September  1999  The  Marketing  Authorisation  Holder  submitted  a  Type  II  variation 
application  in  accordance  with  Article  6  of  Commission  Regulation  (EC)  No.  542/95  of  10 
March 1995, as amended.  The scope of the variation related to the update in the SPC and PL 
according  to  the  irbesartan  post-marketing  experience  and  new  pharmacokinetic  data.  In 
addition,  on  3  December  1999,  the  MAH  applied  for  changes  of  the  Representative  of  the 
Aprovel Marketing Authorisation Holder following the merger of Sanofi and Synthelabo. 
On 16 December 1999 the CPMP approved the variation. The variation required amendments in 
the  relevant  sections  of  the  Commission  Decision  and  the  EPAR.  The  European  Commission 
amended the Decision on 25 April 2000.  
The Marketing Authorisation Holder submitted to the EMEA 19 November 1999 an application 
for  one  type  I  variation  falling  within  the  scope  of  item  No  12  of  Annex  I  to  Commission 
Regulation (EC) No 542/95, as amended. The Marketing Authorisation Holder applied for: 
A minor change in the manufacturing process of the active substance. 
On 21 December 1999, the EMEA issued the corresponding notification. This variation did not 
require amendments to the Commission Decision. 
2/4 
   EMEA 2004 
 
 
 
 
 
 
Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below: 
Scope 
Application 
number 
Type of 
modification1 
Update of Summary of Product Characteristics and Package Leaflet 
The SPC was updated following the assessment of the 4th PSUR. 
Extension of shelf-life of the active substance as foreseen at time of 
authorisation  
Change in test procedure for starting material/intermediate used in 
manuf. of active substance 
Update of Summary of Product Characteristics and Package Leaflet 
The SPC was updated regarding the information in case of 
pregnancy. 
Changes to comply with supplements to pharmacopoeias 
Minor change of manufacturing process of the active substance 
Update of the SPC and PL (Point 4.5, 4.8, 6.5) 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Change in pack size for a medicinal product 
Extension of the Indication 
Change in pack size for a medicinal product 
Replacement of an excipient with a comparable excipient 
Change in the manufacturing authorisation 
Change in batch size of finished product  
Change in the manufacturing authorisation 
Change in the test procedure for starting material/intermediate used 
in manufacturing of active substance 
Change in the test procedure for starting material/intermediate used 
in manufacturing of active substance 
Renewal 
Change in the manufacture of the medicinal product 
Minor change of manufacturing process of the active substance 
Minor change in labelling or package leaflet not connected with the 
SPC (Art. 61.3 Notification) 
Update of Summary of Product Characteristics and Package Leaflet 
Extension of shelf-life or retest period of the active substance 
Change in or addition of manufacturer(s) of active substance 
Minor change of manufacturing process of the active substance 
II/17 
I/18 
I/19 
II/20 
I/21 
I/22 
II/23 
I/24 
I/25 
I/26 
I/27 
I/28 
II/29 
I/30 
I/31 
I/32 
I/33 
I/34 
I/35 
I/36 
R/37 
I/38 
I/39 
N/40 
II/41 
I/42 
I/43 
I/44 
II 
I  
I 
II 
I 
I 
II 
I 
I 
I 
I 
I 
II 
I 
I 
I 
I 
I 
I 
I 
R 
I 
I 
N 
II 
I 
I 
I 
Notification/ 
Opinion 
issued on2 
27.07.00 
Commission 
Decision 
Issued/amen
ded on 
14.11.00 
26.10.00 
15.01.01 
21.11.00 
N/A 
14.12.00 
23.04.01 
20.03.01 
26.03.01 
26.04.01 
02.05.01 
20.09.01 
13.07.01 
10.04.02 
08.10.01 
13.07.01 
08.10.01 
13.07.01 
08.10.01 
20.09.01 
20.09.01 
27.02.02 
20.09.01 
12.10.01 
11.01.02 
26.11.01 
12.06.02 
11.04.02 
22.12.01 
08.03.02 
10.04.02 
02.05.02 
10.04.02 
30.04.02 
25.07.02 
29.10.02 
05.06.02 
18.06.02 
19.12.02 
17.01.03 
17.01.03 
07.03.03 
25.04.03 
28.07.03 
21.03.03 
01.04.03 
23.04.03 
29.04.03 
11.06.03 
17.06.03 
1 In accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended: I refers to a 
minor variation (Type I variation); II refers to a major variation (Type II variation); I/II refers to a minor 
variation following the procedure set out in Article 6, 7 and 8 of the Regulation; X refers to an Annex II 
application. 
T refers to a transfer of a Marketing Authorisation in accordance with Commission Regulation (EC) No 2141/96 
of 7 November 1996.  
N refers to a notification in accordance with Article 10(3) of Council Directive 92/27/EEC of 31 March 1992. 
2 For Notifications and Type I variations, the date of entry into force of the change is the EMEA Notification 
date. The Commission Decision will be amended accordingly. 
3/4 
   EMEA 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                            
 
Minor change of manufacturing process of the active substance 
Change or addition of a new pharmaceutical form 
Change in supplier of an intermediate compound used in 
manufacture of the active substance 
Minor change in the manufacturing process of the active substance 
Change in BR/QC testing - repl./add. of batch control/testing site 
and replacement/add. of manufacturing site: All other manufacturing 
operations ex. batch release 
Change in manuf. of active substance without Ph. Eur. certificate - 
change in manuf. Site 
Update of Summary of Product Characteristics, Labelling and 
Package Leaflet 
Minor change in the manufacturing process of the active substance 
Change in BR/QC testing - repl./add. manuf. responsible for BR - 
not incl. BC/testing 
Replacement/add. of manufacturing site: Secondary packaging site 
and Change in BR/QC testing - repl./add. manuf. responsible for BR 
- not incl. BC/testing 
Change in manuf. of active substance without Ph. Eur. certificate - 
change in manuf. Site 
Change in manuf. of active substance without Ph. Eur. certificate - 
change in manuf. Site 
Minor change in the manufacturing process of the active substance 
I/45 
X/46 
I/47 
I/48 
IB/49 
IB/50 
II/51 
IB/52 
IA/53 
IA/54 
IB/55 
IB/56 
IB/57 
I 
X 
I 
I 
IB 
IB 
II 
IB 
IA 
IA 
IB 
IB 
IB 
12.06.03 
17.06.03 
22.10.03 
02.03.04 
31.10.03 
12.11.03 
10.11.03 
23.12.03 
14.04.04 
- 
- 
- 
03.06.04 
02.08.04 
01.07.04 
30.06.04 
30.06.04 
28.07.04 
29.07.04 
10.08.04 
- 
- 
- 
- 
- 
- 
4/4 
   EMEA 2004 
 
 
 
 
 
 
 
 
